Barclays PLC increased its stake in Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) by 412.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 62,856 shares of the company’s stock ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...

CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company ...

Background: Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiomyopathy characterized by high risks of sustained ventricular tachycardia (sVT) and sudden cardiac death. Identifying patients ...

and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is ...

Its development of a gene therapy candidate for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) addresses a significant unmet need with minimal competition, potentially opening new ...

Its product pipeline include SGT-003 for duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy, among ...

The 1990 SCD of Hank Gathers, a 23-year-old basketball player following a dose reduction of beta-blocker therapy prescribed for a history of ventricular tachycardia (VT), leading to ... long QT ...

1 Department of Cardiology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China 2 Department of Emergency, Shenzhen Second People's Hospital, The ...

It has been shown to terminate ventricular tachycardia, and it has been given to suppress multiple ventricular extrasystoles. 1,2 The drug has been administered as an intravenous bolus or as a ...